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Poster Session I S295cell infiltration. In contrast, no WT1 expression was observed when
disease was absent.
Our findings suggest an association between the emergence of
WT1-specific T cells and graft-versus-myeloma effect in pts being
treated for relapsed MM.246
UPFRONT TANDEM AUTOLOGOUS STEM CELL TRANSPLANT IS SUPERIOR
THAN AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANT AFTER
FAILURE OF 1ST AUTOLOGOUS TRANSPLANT IN PATIENTS WITH MULTI-
PLE MYELOMA
Bachier, C., Wong, A., Shaughnessy, P., LeMaistre, C.F. Texas Trans-
plant Institute, San Antonio, TX
Disease progression remains the main cause of treatment failure
after autologous stem cell transplant (SCT) in patients with multiple
myeloma (MM). It is unclear what is the best salvage therapy after
failure of a 1st autologous SCT in MM.
We performed a retrospective study comparing 2nd autologous
(auto-auto) versus 2nd allogeneic (auto-allo) SCT in patients pro-
gressing or relapsing after their 1st autologous SCT and compare
their outcomes with patients receiving sequential planned double au-
tologous (tandem) SCT as part of their upfront therapy for MM.
The data was collected from CIBMTR reports and medical re-
cords at Texas Transplant Institute from 2001 to 2010. Patient’s
characteristics and outcomes are described in table. Response to 1st
and 2nd SCT was determined at 100 days post transplant and classi-
fied as good (stringent complete remission [sCR], complete remis-
sion [CR], very good partial remission [VGPR]) or poor (partial
remission [PR], stable disease [SD] or progressive disease [PD]).
All patients in the auto-allo group received a reduced intensity reg-
imen. The overall survival was calculated from the date of the 2nd
transplant to the known date of death in all groups. Patients in the
auto-allo group (15.9 months) had a worse median survival than in
the auto-auto group (39 months) with both of them having a worse
survival compared to patients undergoing tandem transplants
(64.3) (p value 5 0.003).
Forward stepwiseCox regression analysis was used tomeasure fac-
tors affecting overall survival. Factors used for analysis included age,
cytogenetics (high risk 5 mutated p53, t(14;16), t(4;14), del 13), In-
ternational Staging System (ISS) before 1st and 2nd SCT, use of
maintenance therapy after 1st SCT, days from diagnosis to 1st SCT
and days from 1st to 2nd SCT, CD34+ cells infused at 1st and 2nd
SCT. Age and ISS of III at 2nd transplant were identified as factors
affecting survival in the auto-auto group (hazard ration of 1.081
and 5.700, respectively).Table. Patient Characteristics and Outcomes
Tandem (n 5 29)
Median age, years (range) 62 (41-78)
Median days from diagnosis to 1st transplant 224.5 (93-1344)
Median days from 1st to 2nd transplant 149 (99-189)
Median total CD34+ cell infused 1st transplant 3.29 (2-12)
Median total CD34+ cell infused 2nd transplant 3.22 (2-9)
Median WBC engraftment 11 (9-13)
Median Platelet engraftment 16 (10-19)
Cytogenetics-High Risk 17%
ISS at 1st transplant I 31%
ISS at 1st transplant II 34%
ISS at 1st transplant III 14%
ISS at 2nd transplant I 48%
ISS at 2nd transplant II 17%
ISS at 2nd transplant III 10%
Response to 1st transplant Good 10%
Response to 1st transplant Poor 80%
Response to 2nd transplant Good 52%
Response to 2nd transplant Poor 80%
Median Followup (months) 57.1 (3.4-76.7)In conclusion, overall survival after salvage from 2nd autologous
stem cell transplant is longer than after a 2nd allogeneic transplant.
Upfront, planned tandem autologous stem cell transplant is superior
to both salvage strategies. Larger, randomized trials are needed to
confirm these results.247
RETROSPECTIVE REVIEW OF DPACE THERAPY AS A SALVAGE REGIMEN
IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA PRIOR TO AUTOLO-
GOUS STEM CELL TRANSPLANT
Snider, J.N.1, Stelts, S.D.2, Awan,M.3, Raza,M.3, Goorha, S.3 1Univer-
sity of Tennessee Health Sciences Center, Memphis, TN; 2Methodist
University Hospital, Memphis, TN; 3Boston Baskin Cancer Foundation,
Germantown, TN
Background: The landscape of multiple myeloma (MM) treatment
has improved substantially since the introduction of novel agents
thalidomide, bortezomib and lenolidomide. However, it is not al-
ways clear what therapy would be effective in patients after they
progress with these novel agents. To identify effective salvage ther-
apy, we performed a retrospective review of DPACE (dexametha-
sone, cisplatin, doxorubicin, cyclophosphamide, and etoposide)
chemotherapy in pretreated MM patients who were candidates for
autologous stem cell transplant (ASCT).
Methods: Review of electronic medical records at our institution
from January 1, 2005 to July 31, 2011 was performed. Eligible sub-
jects were $18 years old with a diagnosis of MM that received
DPACE after their disease had progressed with chemotherapy in-
cluding a novel agent and were transplant candidates. Data collected
included ISS stage at diagnosis, response to therapy, safety data, time
to transplant, and time to progression and death.
Results:We evaluated 24 patients who had received a median num-
ber of 2 (range 1-4) prior therapies, excluding single agent dexame-
thasone.Prior to DPACE, 38% (n 5 9) had undergone at least one
ASCT. The median number of DPACE cycles was 2 (range 1-5).
Median age was 57 (range 46 - 75); 75 % (n 5 18) were African-
American and 25% (n 5 6) were Caucasian. Partial response or
greater was achieved in 79% (n 5 19), stable disease in 13% (n 5
3), and 8% had progressive disease (n5 2). Dose reduction occurred
in 25% (n 5 6) of patients with dose reductions ranging from 20 to
50%. Sixteen patients (67%) proceeded to ASCT including five of
the 9 (55%) who had prior ASCT. Median time to transplant was
3 months (range 2 -11) from first DPACE cycle. Six patients experi-
enced CTCAE v4.0 grade 3/4 neutropenia with only 16% (n5 4) fe-
brile neutropenia. All patients received growth factor support. Grade
3/4 thrombocytopenia (n5 2), anemia (n5 2), and mucositis (n5 2)Auto-Auto (n 5 32) Auto-Allo (n 5 10)
62.5 (45-81) 54 (43-63)
226 (117-1074) 254.5 (101-416)
847 (210-4158) 350 (88-1281)
5.87 (2-28) 6.03 (2-14)
4.47 (2-19) 5.25 (3-11)
11 (9-47) N/A
15 (10-23) N/A
3% 10%
41% 40%
12% 0
6% 10%
53% 40%
9% 0
13% 10%
63% 70%
25% 20%
47% 30%
25% 20%
24.6 (10.5-87.8) 48.0 (31.9-64.0)
